Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
15 papers
Recent·Most cited
M. Karim, M. Mishra, C.-W. Lo, S. Saul, H. B. Cagirici, D. H. Nhu Tran, A. Agrawal, L. Ghita, A. Ojha, M. P. East, K. Anbro Gammeltoft, M. Kumar Sahoo, G. L. Johnson, S. Das, D. Jochmans, , S. Einav
RMC-113 inhibits PIP4K2C and PIKfyve, reversing SARS-CoV-2-induced autophagic flux impairment and showing antiviral effects.
bioRxiv · Apr 15, 2024Microbiology
R. Abdelnabi, P. Maes, S. de Jonghe, B. Weynand, J. Neyts
This study shows that combining GS-441524 and molnupiravir significantly reduces SARS-CoV-2 viral load in infected Syrian hamsters.
bioRxiv · Oct 13, 2022Microbiology
D. Jochmans, C. Liu, K. Donckers, A. Stoycheva, S. Boland, S. K. Stevens, C. De Vita, B. Vanmechelen, P. Maes, B. S. Trüeb, N. Ebert, V. Thiel, S. De Jonghe, L. Vangeel, D. Bardiot, , K. Vandyck
This paper identifies three substitutions in SARS-CoV-2 3CLpro that confer resistance to nirmatrelvir and other 3CLpro inhibitors in vitro.
bioRxiv · Jun 7, 2022 · PreprintMicrobiology
R. Abdelnabi, C. S. Foo, S. Kaptein, R. Boudewijns, L. Vangeel, S. De Jonghe, D. Jochmans, B. Weynand, J. Neyts
This paper establishes a SCID mouse model infected with the SARS-CoV-2 beta B.1.351 variant to evaluate antiviral efficacy, showing significant reduction in viral load with Molnupiravir and Nirmatrelvir.
bioRxiv · May 13, 2022Microbiology
M. Karim, S. Saul, L. Ghita, M. K. Sahoo, C. Ye, N. Bhalla, J. Jin, J.-G. Park, B. Martinez-Gualda, M. Patrick East, G. L. Johnson, B. A. Pinsky, L. Martinez-Sobrido, C. R. M. Asquith, A. Narayanan, , S. Einav
This study shows that Numb-associated kinases are essential for SARS-CoV-2 infection and that inhibiting them can suppress viral infection in human lung cells.
bioRxiv · Mar 18, 2022 · PreprintMicrobiology
C. S.-Y. Foo, R. Abdelnabi, L. Vangeel, S. De Jonghe, D. Jochmans, B. Weynand, J. Neyts
This study shows that Ivermectin does not reduce SARS-CoV-2 lung viral load or improve lung pathology in Syrian hamsters and does not enhance Molnupiravir's effect.
bioRxiv · Feb 22, 2022Microbiology
W. Chiu, L. Verschueren, C. Van den Eynde, C. Buyck, S. De Meyer, D. Jochmans, D. Bojkova, S. Ciesek, J. Cinatl, S. De Jonghe, P. Leyssen, J. Neyts, M. Van Loock, E. Van Damme
The paper develops a high-throughput screening assay to evaluate 5676 phase 1 compounds for in vitro anti-SARS-CoV-2 activity, identifying eight candidates but finding only remdesivir suitable for further clinical development.
bioRxiv · Feb 2, 2022Immunology
L. Vangeel, W. Chiu, S. De Jonghe, P. Maes, B. Slechten, J. Raymenants, E. Andre, P. Leyssen, J. Neyts, D. Jochmans
The paper evaluates the antiviral activity of remdesivir, molnupiravir, and nirmatrelvir against SARS-CoV-2 variants, finding they remain effective.
bioRxiv · Dec 27, 2021Microbiology
R. Abdelnabi, C. S.-Y. Foo, D. Jochmans, L. Vangeel, S. De Jonghe, P. Augustijns, R. Mols, B. Weynand, T. Wattanakul, R. Hoglund, J. Tarning, C. Mowbray, P. Sjo, F. Escudie, I. Scandale, , J. Neyts
PF-07321332, an oral protease inhibitor, effectively protects Syrian hamsters against SARS-CoV-2 variants of concern, including beta and delta, by preventing infection and transmission.
bioRxiv · Nov 4, 2021Microbiology
A. K. Singh, S. E. Martinez, W. Gu, H. Nguyen, D. Schols, P. H. Herdewijn, S. De Jonghe, K. Das
The paper identifies a transient P-pocket in HIV-1 reverse transcriptase during DNA sliding and demonstrates fragment screening to target this pocket for inhibitor development.
bioRxiv · Jul 3, 2021Biophysics
S. Saul, M. Karim, P.-T. Huang, L. Ghita, W. Chiu, S. Kumar, N. Bhalla, P. Leyssen, C. A. Cohen, K. E. Huie, C. Tindle, M. Sibai, B. A. Pinsky, S. Das, P. Ghosh, , S. Einav
This study identifies lapatinib, an ErbB inhibitor, as a broad-spectrum antiviral that suppresses SARS-CoV-2 and VEEV replication, inflammation, and lung injury through ErbB-mediated mechanisms.
bioRxiv · May 15, 2021Microbiology
T. N. D. Do, K. Donckers, L. Vangeel, A. K. Chatterjee, P. A. Gallay, M. D. Bobardt, J. P. Bilello, T. Cihlar, S. De Jonghe, J. Neyts, D. Jochmans
This study develops a SARS-CoV-2 replication model using primary human airway epithelial cells to test antiviral agents, finding that remdesivir and interferons inhibit replication while AT-511 does not.
bioRxiv · Mar 25, 2021Microbiology
C. S. Foo, R. Abdelnabi, S. J. F. Kaptein, X. Zhang, S. ter Horst, R. Mols, L. Delang, J. Rocha-Pereira, L. Coelmont, P. Leyssen, K. Dallmeier, V. Vergote, E. Heylen, L. Vangeel, A. K. Chatterjee, , J. Neyts
Nelfinavir reduces SARS-CoV-2-induced lung pathology in Syrian hamsters without affecting viral RNA or infectious titers.
bioRxiv · Feb 1, 2021 · PreprintMicrobiology
R. Abdelnabi, C. S. Foo, S. J. F. Kaptein, X. Zhang, L. Langendries, L. Vangeel, J. Breuer, J. Pang, R. Williams, V. Vergote, E. Heylen, P. Leyssen, K. Dallmeier, L. Coelmont, D. Jochmans, , J. Neyts
This study shows that combining Molnupiravir and Favipiravir significantly enhances antiviral efficacy against SARS-CoV-2 in hamsters, reducing viral titers by 4.5 log10 and eliminating detectable virus in 60% of treated animals.
bioRxiv · Dec 10, 2020Microbiology
E. Van Damme, S. De Meyer, D. Bojkova, S. Ciesek, J. Cinatl, S. De Jonghe, D. Jochmans, P. Leyssen, C. Buyck, J. Neyts, M. Van Loock
This paper assesses the in vitro antiviral activity of itraconazole and its metabolite against SARS-CoV-2, finding EC50 values of 2.3 μM and 3.6 μM, respectively, and reports no clinical efficacy in hospitalized patients.
bioRxiv · Nov 13, 2020Pharmacology & Toxicology